A_DT
3_CD
'_``
--_NN
&gt;_JJR
5_CD
'_''
XPB_NN
helicase_NN
defect_NN
in_IN
repair\/transcription_NN
factor_NN
TFIIH_NN
of_IN
xeroderma_NN
pigmentosum_NN
group_NN
B_NN
affects_VBZ
both_CC
DNA_NN
repair_NN
and_CC
transcription_NN
._.

XPB_NN
is_VBZ
a_DT
subunit_NN
of_IN
the_DT
basal_JJ
transcription_NN
factor_NN
TFIIH_NN
,_,
which_WDT
is_VBZ
also_RB
involved_VBN
in_IN
nucleotide_NN
excision_NN
repair_NN
-LRB-_-LRB-
NER_NN
-RRB-_-RRB-
and_CC
potentially_RB
in_IN
cell_NN
cycle_NN
regulation_NN
._.

A_DT
frameshift_NN
mutation_NN
in_IN
the_DT
3_CD
'_POS
-_:
end_NN
of_IN
the_DT
XPB_NN
gene_NN
is_VBZ
responsible_JJ
for_IN
a_DT
concurrence_NN
of_IN
two_CD
disorders_NNS
:_:
xeroderma_NN
pigmentosum_NN
-LRB-_-LRB-
XP_NN
-RRB-_-RRB-
and_CC
Cockayne_NN
's_POS
syndrome_NN
-LRB-_-LRB-
CS_NN
-RRB-_-RRB-
._.

We_PRP
have_VBP
isolated_VBN
TFIIH_NN
from_IN
cells_NNS
derived_VBN
from_IN
a_DT
patient_NN
-LRB-_-LRB-
XP11BE_NN
-RRB-_-RRB-
who_WP
carries_VBZ
this_DT
frameshift_NN
mutation_NN
-LRB-_-LRB-
TFIIHmut_NN
-RRB-_-RRB-
and_CC
from_IN
the_DT
mother_NN
of_IN
this_DT
patient_NN
-LRB-_-LRB-
TFIIHwt_NN
-RRB-_-RRB-
to_TO
determine_VB
the_DT
biochemical_JJ
consequences_NNS
of_IN
the_DT
mutation_NN
._.

Although_IN
identical_JJ
in_IN
composition_NN
and_CC
stoichiometry_NN
to_TO
TFIIHwt_NN
,_,
TFIIHmut_NN
shows_VBZ
a_DT
reduced_VBN
3_CD
'_``
--_NN
&gt;_JJR
5_CD
'_''
XPB_NN
helicase_NN
activity_NN
._.

A_DT
decrease_NN
in_IN
helicase_NN
and_CC
DNA-dependent_JJ
ATPase_NN
activities_NNS
was_VBD
also_RB
observed_VBN
with_IN
the_DT
mutated_VBN
recombinant_JJ
XPB_NN
protein_NN
._.

The_DT
XPB_NN
mutation_NN
causes_VBZ
a_DT
severe_JJ
NER_NN
defect_NN
._.

In_IN
addition_NN
,_,
we_PRP
provide_VBP
evidence_NN
for_IN
a_DT
decrease_NN
in_IN
basal_JJ
transcription_NN
activity_NN
in_FW
vitro_FW
._.

The_DT
latter_JJ
defect_NN
may_MD
provide_VB
an_DT
explanation_NN
for_IN
many_JJ
of_IN
the_DT
XP_NN
and_CC
CS_JJ
symptoms_NNS
that_WDT
are_VBP
difficult_JJ
to_TO
rationalize_VB
based_VBN
solely_RB
on_IN
an_DT
NER_NN
defect_NN
._.

Thus_RB
,_,
this_DT
work_NN
presents_VBZ
the_DT
first_JJ
detailed_JJ
analysis_NN
of_IN
a_DT
naturally_RB
occurring_VBG
mutation_NN
in_IN
a_DT
basal_JJ
transcription_NN
factor_NN
and_CC
supports_VBZ
the_DT
concept_NN
that_IN
the_DT
combined_JJ
XP\/CS_NN
clinical_JJ
entity_NN
is_VBZ
actually_RB
the_DT
result_NN
of_IN
a_DT
combined_JJ
transcription\/repair_NN
deficiency_NN
._.

